NetworkNewsBreaks – DarioHealth Corp. (NASDAQ: D
Post# of 188
(Total Views: 267)
Posted On: 01/13/2021 3:38:39 PM
NetworkNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Appoints Diabetes, Behavioral Health Experts to Scientific Advisory Board
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced the appointment of two renowned experts to its Scientific Advisory Board (“SAB”). Dr. Marilyn Ritholz, psychologist at Joslin Diabetes Center, a Harvard Medical School affiliate, and Dr. David Horwitz, former global chief medical officer of Johnson & Johnson Diabetes Institute, join SAB chairman Eric Milledge; the prestigious board is focused on advancing Dario’s technical leadership, helping to guide the development of the company’s bold technology road map and advancing Dario’s DTx (“DTx”) platform by integrating members’ comprehensive experience and expertise into the company offering. Ritholz and Horwitz are recognized as experts in the fields of diabetes, metabolism, and behavioral health. A senior psychologist at the Joslin Diabetes Center, Ritholz is also on the faculty at Beth Israel Deaconess Medical Center (“BIDMC”) and is an assistant professor of psychology at Harvard Medical School. A senior consultant with Numerof & Associates, Horwitz also serves as president of DLH Biomedical Consulting and has previously held faculty positions in the medical schools at the University of Chicago and the University of Illinois. “My objective is to populate Dario’s SAB with renowned members of the global medical community who align with Dario’s approach to empower individuals to achieve meaningful, sustainable behavior change through highly personalized, AI-driven experiences that adapt dynamically through a member’s journey,” said Milledge in the press release. “Dr. Ritholz’s accomplishments at the Joslin Diabetes Center, a Harvard Medical School affiliate, include a leading practice focused on the intersection of psychology and diabetes management in adolescents and adults. Her expertise will be key in refining aspects of our technology for improved patient-provider interactions and, ultimately, better care. Dr. Horwitz’s experiences as a Board-Certified internist and endocrinologist, coupled with his knowledge of the healthcare ecosystem, will lay the foundation for a strong board committed to improving patient care. I am excited to work with them as we continue to build out the SAB and drive continued innovation of Dario’s platform.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced the appointment of two renowned experts to its Scientific Advisory Board (“SAB”). Dr. Marilyn Ritholz, psychologist at Joslin Diabetes Center, a Harvard Medical School affiliate, and Dr. David Horwitz, former global chief medical officer of Johnson & Johnson Diabetes Institute, join SAB chairman Eric Milledge; the prestigious board is focused on advancing Dario’s technical leadership, helping to guide the development of the company’s bold technology road map and advancing Dario’s DTx (“DTx”) platform by integrating members’ comprehensive experience and expertise into the company offering. Ritholz and Horwitz are recognized as experts in the fields of diabetes, metabolism, and behavioral health. A senior psychologist at the Joslin Diabetes Center, Ritholz is also on the faculty at Beth Israel Deaconess Medical Center (“BIDMC”) and is an assistant professor of psychology at Harvard Medical School. A senior consultant with Numerof & Associates, Horwitz also serves as president of DLH Biomedical Consulting and has previously held faculty positions in the medical schools at the University of Chicago and the University of Illinois. “My objective is to populate Dario’s SAB with renowned members of the global medical community who align with Dario’s approach to empower individuals to achieve meaningful, sustainable behavior change through highly personalized, AI-driven experiences that adapt dynamically through a member’s journey,” said Milledge in the press release. “Dr. Ritholz’s accomplishments at the Joslin Diabetes Center, a Harvard Medical School affiliate, include a leading practice focused on the intersection of psychology and diabetes management in adolescents and adults. Her expertise will be key in refining aspects of our technology for improved patient-provider interactions and, ultimately, better care. Dr. Horwitz’s experiences as a Board-Certified internist and endocrinologist, coupled with his knowledge of the healthcare ecosystem, will lay the foundation for a strong board committed to improving patient care. I am excited to work with them as we continue to build out the SAB and drive continued innovation of Dario’s platform.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)